Healthcare U.S. Community

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more

In a nutshell: Hims & Hers’ invests heavily and will reap benefits sooner or later. Every step we see has the long term goal on the background, to be a front door for customers, the delivery channel, the platform.Read more

I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone.Read more

RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.Read more

COMPANY ANALYSIS : Hims & Hers is a telehealth company founded in 2017 with the mission of improving wellness through accessible healthcare. The company operates primarily in the United States, Canada and Europe growing largely through the acquisition of the telehealth platform ZAVA, planning on further international growth.Read more

UnitedHealth (UNH): A Data Giant Hidden in an Insurer's Crisis Investment Narrative – February 2026 Price Target (12m): $395.00 (+35% upside) Rating: Strong Buy (Contrarian) 1. The Core Thesis: The "Optum" Mispricing The market is currently valuing UnitedHealth through the narrow lens of a traditional insurer struggling with Medicare Advantage (MA) rate cuts and CMS regulatory headwinds for 2027.Read more

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Read more

One main problem in any surgery is access to the operative site: This means cutting through and bleeding from healthy tissue with infections, scars, pain, prolonged hospital stays and costs. Focal therapy with HIFU takes this burden out of the equation, which has been any surgeon's dream for centuries.Read more

Valuation: UnitedHealth Group’s new CEO, Stephen Hemsley, has reaffirmed confidence in the company’s ability to return to its long-term earnings growth target of 13%–16% by 2026. Despite recent headwinds—including elevated Medicare Advantage costs, a major cyberattack, and leadership transitions—Hemsley emphasized that these challenges are manageable and well within the company’s capacity to address.Read more